Table III.
NK cell response from six donors against targets expressing gpUL18
| Donor | % LIR-1+ NKa |
% LIR-1+ NK Inhibitionb |
% LIR-1− NK Activationb |
% Total NK Activationb |
|---|---|---|---|---|
| 705G | 28.6 | 34.6 ± 6 | 53.3 ± 1 | 24.6 ± 1 |
| 683N | 17.5 | 57.7 ± 9 | 52.7 ± 9 | 29.2 ± 10 |
| 420A | 55.5 | 44.5 ± 1 | 32.9 ± 12 | NSc |
| 004W | 17.1 | 40.2 ± 13 | 21.6 ±7 | NS |
| 907M | 30 | 29.6 ± 9 | 19.2 ±1 | NS |
| 421V | 55.4 | 28.7 ± 3 | 18.3 ± 10 | NS |
a
Percentages of LIR-1+ cells among CD3−CD56+ NK cells after PBMC incubation with IFN-α for 16 h.
b
Percentages of inhibition or activation comparing NK degranulation ± SEM between RAd-Ctrl- and RAd-UL18-infected targets.
c
NS, with NK inhibition or activation <10%.